Middle East and Africa Dengue Treatment Market

List of Tables

Middle East and Africa dengue treatment market is expected to reach USD 116.81 million by 2031, from USD 49.55 million in 2023, growing at the CAGR of 11.3% in the forecast period of 2024 to 2031.

Market Segmentation:

Middle East and Africa Dengue Treatment Market, By Strains (DENV-2, DENV-3, DENV-1, DENV-4, and Others), Type (Vaccines and Acetaminophen), Severity (Mild to Moderate Dengue and Severe Dengue), Route of Administration (Parenteral and Oral), Mode of Purchase (Prescription and Over-the-Counter (OTC)), Gender (Male and Female), Age (Adult, Pediatric, and Geriatric), End User (Hospital, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies), By Countries (South Africa, Egypt, Saudi Arabia, U.A.E., Israel, and Rest of Middle East and Africa) - Industry Trends and Forecast to 2031

Overview of Middle East and Africa Dengue Treatment Market Dynamics:

Driver
Rising dengue incidence rate result in the demand for effective treatment
Restrain
Delay in the approval process of vaccines
Opportunity
Growing number of pipeline vaccines for dengue treatment

Market Players:

The key market players operating in the Middle East and Africa dengue treatment market are listed below:

Sanofi
Viatris Inc.
Johnson & Johnson
GSK plc.
Baxter
Fresenius Kabi USA
Pfizer
Hikma Pharmaceuticals PLC
Sun Pharmaceutical Industries Ltd
Teva Pharmaceuticals USA, Inc.
Aurobindo Pharma

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATIONS
1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 DBMR TRIPOD DATA VALIDATION MODEL
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.6 MULTIVARIATE MODELLING
2.7 MARKET APPLICATION COVERAGE GRID
2.8 PRODUCT LIFELINE CURVE
2.9 DBMR MARKET POSITION GRID
2.10 VENDOR SHARE ANALYSIS
2.11 SECONDARY SOURCES
2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES

5 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: REGULATIONS

5.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT
5.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT
5.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK
5.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE
5.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK

6 MARKET OVERVIEW

6.1 DRIVERS
- 6.1.1 RISING DENGUE INCIDENCE RATE RESULT IN THE DEMAND FOR EFFECTIVE TREATMENT
- 6.1.2 RISING WAVE OF DENGUE VACCINE LAUNCHES
- 6.1.3 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS
- 6.1.4 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES
6.2 RESTRAINTS
- 6.2.1 DELAY IN THE APPROVAL PROCESS OF VACCINES
- 6.2.2 LACK OF AWARENESS AND HEALTHCARE INFRASTRUCTURE FOR TREATMENT OF DENGUE
- 6.2.3 DIFFICULTY IN THE DETECTION ASSAY FOR DENGUE
6.3 OPPORTUNITIES
- 6.3.1 STRATEGIC COLLABORATION WITHIN THE PHARMACEUTICAL INDUSTRY FUELS THE MARKET
- 6.3.2 GROWING NUMBER OF PIPELINE VACCINES FOR DENGUE TREATMENT
- 6.3.3 RISING R&D INVESTMENT AND ACTIVITIES
6.4 CHALLENGES
- 6.4.1 HEALTHCARE SERVICES ARE LIMITEDLY ACCESSIBLE IN RURAL AREAS
- 6.4.2 HIGH COSTS OF TREATMENT RESTRICT THE FEASIBILITY OF COST-EFFECTIVE SOLUTIONS

7 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS

7.1 OVERVIEW
7.2 DENV-2
7.3 DENV-3
7.4 DENV-1
7.5 DENV-4
7.6 OTHERS

8 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY TYPE

8.1 OVERVIEW
8.2 VACCINES
- 8.2.1 DENGVAXIA (CYD-TDV)
- 8.2.2 QDENGA
8.3 ACETAMINOPHEN
- 8.3.1 PARENTERAL
- 8.3.2 ORAL
- 8.3.3 OTHER

9 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY SEVERITY

9.1 OVERVIEW
9.2 MILD TO MODERATE DENGUE
9.3 SEVERE DENGUE

10 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW
10.2 PARENTERAL
- 10.2.1 SUB-CUTANEOUS
- 10.2.2 INTRAVENOUS
10.3 ORAL
- 10.3.1 TABLET
- 10.3.2 CAPSULES
- 10.3.3 OTHERS

11 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE

11.1 OVERVIEW
11.2 PRESCRIPTION
11.3 OVER-THE-COUNTER (OTC)

12 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY GENDER

12.1 OVERVIEW
12.2 MALE
12.3 FEMALE

13 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY AGE

13.1 OVERVIEW
13.2 ADULT
13.3 PEDIATRIC
13.4 GERIATRIC

14 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY END USER

14.1 OVERVIEW
14.2 HOSPITAL
14.3 SPECIALTY CLINICS
14.4 HOME HEALTHCARE
14.5 OTHERS

15 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW
15.2 RETAIL PHARMACIES
15.3 HOSPITAL PHARMACIES
15.4 ONLINE PHARMACIES

16 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY REGION

16.1 MIDDLE EAST AND AFRICA
- 16.1.1 EGYPT
- 16.1.2 SAUDI ARABIA
- 16.1.3 SOUTH AFRICA
- 16.1.4 U.A.E
- 16.1.5 ISRAEL
- 16.1.6 REST OF MIDDLE EAST AND AFRICA

17 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 SANOFI
- 19.1.1 COMPANY SNAPSHOT
- 19.1.2 REVENUE ANALYSIS
- 19.1.3 COMPANY SHARE ANALYSIS
- 19.1.4 PRODUCT PORTFOLIO
- 19.1.5 RECENT DEVELOPMENTS
19.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED
- 19.2.1 COMPANY SNAPSHOT
- 19.2.2 REVENUE ANALYSIS
- 19.2.3 COMPANY SHARE ANALYSIS
- 19.2.4 PRODUCT PORTFOLIO
- 19.2.5 RECENT DEVELOPMENTS
19.3 VIATRIS INC.
- 19.3.1 COMPANY SNAPSHOT
- 19.3.2 REVENUE ANALYSIS
- 19.3.3 COMPANY SHARE ANALYSIS
- 19.3.4 PRODUCT PORTFOLIO
- 19.3.5 RECENT DEVELOPMENTS
19.4 JOHNSON & JOHNSON SERVICES, INC.
- 19.4.1 COMPANY SNAPSHOT
- 19.4.2 REVENUE ANALYSIS
- 19.4.3 COMPANY SHARE ANALYSIS
- 19.4.4 PRODUCT PORTFOLIO
- 19.4.5 RECENT DEVELOPMENT
19.5 GSK PLC.
- 19.5.1 COMPANY SNAPSHOT
- 19.5.2 REVENUE ANALYSIS
- 19.5.3 COMPANY SHARE ANALYSIS
- 19.5.4 PRODUCT PORTFOLIO
- 19.5.5 RECENT DEVELOPMENTS
19.6 AUROBINDO PHARMA
- 19.6.1 COMPANY SNAPSHOT
- 19.6.2 REVENUE ANALYSIS
- 19.6.3 PRODUCT PORTFOLIO
19.7 BAXTER
- 19.7.1 COMPANY SNAPSHOT
- 19.7.2 REVENUE ANALYSIS
- 19.7.3 PRODUCT PORTFOLIO
19.8 FRESENIUS KABI USA
- 19.8.1 COMPANY SNAPSHOT
- 19.8.2 PRODUCT PORTFOLIO
- 19.8.3 RECENT DEVELOPMENTS
19.9 HIKMA PHARMACEUTICALS
- 19.9.1 COMPANY SNAPSHOT
- 19.9.2 REVENUE ANALYSIS
- 19.9.3 PRODUCT PORTFOLIO
- 19.9.4 RECENT DEVELOPMENT
19.10 PERRIGO COMPANY PLC
- 19.10.1 COMPANY SNAPSHOT
- 19.10.2 REVENUE ANALYSIS
- 19.10.3 PRODUCT PORTFOLIO
- 19.10.4 RECENT DEVELOPMENT
19.11 PFIZER INC.
- 19.11.1 COMPANY SNAPSHOT
- 19.11.2 REVENUE ANALYSIS
- 19.11.3 PRODUCT PORTFOLIO
- 19.11.4 RECENT DEVELOPMENTS
19.12 SUN PHARMACEUTICAL INDUSTRIES LTD
- 19.12.1 COMPANY SNAPSHOT
- 19.12.2 REVENUE ANALYSIS
- 19.12.3 PRODUCT PORTFOLIO
- 19.12.4 RECENT DEVELOPMENT
19.13 TEVA PHARMACEUTICALS USA, INC.
- 19.13.1 COMPANY SNAPSHOT
- 19.13.2 REVENUE ANALYSIS
- 19.13.3 PRODUCT PORTFOLIO
- 19.13.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

LIST OF TABLES

TABLE 1 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION
TABLE 2 IMPACT OF DELAY IN APPROVAL PROCESS
TABLE 3 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 13 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 14 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 17 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 18 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA MILD TO MODERATE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA SEVERE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA ORAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA PRESCRIPTION IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA OVER-THE-COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA MALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA FEMALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA ADULT IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA PEDIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA GERIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA HOSPITAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA SPECIALITY CLINICS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA RETAIL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA HOSPITAL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA ONLINE PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 50 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 51 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 53 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 54 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 55 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 56 MIDDLE EAST AND AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 57 MIDDLE EAST AND AFRICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 58 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 59 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 60 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 61 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 62 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 63 EGYPT DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 64 EGYPT DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 65 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 66 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 67 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 68 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 69 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 70 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 71 EGYPT DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 72 EGYPT DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 73 EGYPT PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 74 EGYPT ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 75 EGYPT DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 76 EGYPT DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 77 EGYPT DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 78 EGYPT DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 79 EGYPT DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 80 SAUDI ARABIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 81 SAUDI ARABIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 82 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 83 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 84 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 85 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 86 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 87 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 88 SAUDI ARABIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 89 SAUDI ARABIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 90 SAUDI ARABIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 91 SAUDI ARABIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 92 SAUDI ARABIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 93 SAUDI ARABIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 94 SAUDI ARABIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 95 SAUDI ARABIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 96 SAUDI ARABIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 97 SOUTH AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 98 SOUTH AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 99 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 100 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 101 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 102 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 103 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 104 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 105 SOUTH AFRICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 106 SOUTH AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 107 SOUTH AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 108 SOUTH AFRICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 109 SOUTH AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 110 SOUTH AFRICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 111 SOUTH AFRICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 112 SOUTH AFRICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 113 SOUTH AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 114 U.A.E DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 115 U.A.E DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 116 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 117 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 118 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 119 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 120 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 121 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 122 U.A.E DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 123 U.A.E DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 124 U.A.E PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 125 U.A.E ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 126 U.A.E DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 127 U.A.E DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 128 U.A.E DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 129 U.A.E DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 130 U.A.E DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 131 ISRAEL DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)
TABLE 132 ISRAEL DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 133 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 134 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 135 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 136 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 137 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)
TABLE 138 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)
TABLE 139 ISRAEL DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)
TABLE 140 ISRAEL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)
TABLE 141 ISRAEL PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 142 ISRAEL ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)
TABLE 143 ISRAEL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)
TABLE 144 ISRAEL DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)
TABLE 145 ISRAEL DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)
TABLE 146 ISRAEL DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)
TABLE 147 ISRAEL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)
TABLE 148 REST OF MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

LIST OF FIGURES

FIGURE 1 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 7 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID
FIGURE 8 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: SEGMENTATION
FIGURE 11 GROWING PHARMACEUTICAL INDUSTRY IS DRIVING THE GROWTH OF THE MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET FROM 2024 TO 2031
FIGURE 12 ON THE BASIS OF STRAINS, THE DENV-2 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET IN 2024 AND 2031
FIGURE 13 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET
FIGURE 14 FINANCIAL BUDGET FOR VECTOR-BORNE -DISEASES INCLUDING DENGUE IN INDIA
FIGURE 15 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY STRAINS, 2023
FIGURE 16 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY STRAINS, 2024-2031 (USD MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2024-2031)
FIGURE 18 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY TYPE, 2023
FIGURE 20 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY TYPE, 2024-2031 (USD MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY TYPE, CAGR (2024-2031)
FIGURE 22 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY SEVERITY, 2023
FIGURE 24 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY SEVERITY, 2024-2031 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2024-2031)
FIGURE 26 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023
FIGURE 28 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)
FIGURE 30 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2023
FIGURE 32 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2024-2031 (USD MILLION)
FIGURE 33 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2024-2031)
FIGURE 34 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY GENDER, 2023
FIGURE 36 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY GENDER, 2024-2031 (USD MILLION)
FIGURE 37 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY GENDER, CAGR (2024-2031)
FIGURE 38 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY GENDER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY AGE, 2023
FIGURE 40 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY AGE, 2024-2031 (USD MILLION)
FIGURE 41 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY AGE, CAGR (2024-2031)
FIGURE 42 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY AGE, LIFELINE CURVE
FIGURE 43 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY END USER, 2023
FIGURE 44 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY END USER, 2024-2031 (USD MILLION)
FIGURE 45 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY END USER, CAGR (2024-2031)
FIGURE 46 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE
FIGURE 47 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023
FIGURE 48 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)
FIGURE 49 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)
FIGURE 50 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 51 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: SNAPSHOT (2023)
FIGURE 52 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)